Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
1,055 INR | -0.55% | +1.88% | +23.43% |
Apr. 29 | Glenmark Pharmaceuticals Gets US FDA's Final Approval for Generic Pain Relief Medicines | MT |
Apr. 25 | Glenmark Lifesciences' Net Profit Slides in Fiscal Q4 | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+23.43% | 3.59B | |
+19.79% | 43.67B | |
+20.67% | 22.51B | |
+14.04% | 14.6B | |
+14.32% | 13.74B | |
+44.87% | 11.91B | |
-8.37% | 7.04B | |
-0.05% | 6.79B | |
-8.87% | 5.73B | |
+10.21% | 5.42B |
- Stock Market
- Equities
- GLENMARK Stock
- News Glenmark Pharmaceuticals Limited
- Nomura Adjusts Glenmark Pharmaceuticals’ Price Target to INR909 From INR841, Keeps at Neutral